

For Immediate Release

JOLT HEALTH INC. ANNOUNCES Issuance of Common Shares in Satisfaction of Interest Payments to Promissory Note Holders and Interest Payment to Convertible Debenture Holder

VANCOUVER, BC, CANADA (May 25, 2023) – Jolt Health Inc. (formerly Love Pharma Inc.) (“Jolt” and or “the Company”) (CSE:JOLT) (FSE: G1Q0) is pleased to announce that pursuant to a 10% interest bearing convertible debenture issued on October 12, 2022, the Issuer issued a total of 13,765,763 common shares, at \$0.015 per common share in satisfaction of the aggregate interest payment owed by the Issuer of \$195,000 to a Debenture holder. In addition, pursuant to Promissory Notes dated January 23, 2020 and extended to December 31, 2023, the Issuer issued a total of 6,116,913 common shares at \$0.15 per common share in satisfaction of the aggregate per annum interest rate of 5% owing on the Promissory Notes.

The common shares are being issued to arms-length parties, and are subject to a four month hold period. The shares for debt settlement is subject to the approval of the Canadian Securities Exchange.

About Jolt Health Inc.

With a focus on the global sexual Health and Wellness markets, Jolt Health Inc., formerly Love Pharma Inc. (CSE:JOLT) (FSE: G1Q0) was founded in 2020, with a mission to bring to market innovative products that enhance sexual health and wellness while providing an improved quality of life. Jolt holds exclusive licenses to produce, market, package, sell, and distribute patent-protected therapeutic and pharmaceutical products throughout Europe, the United Kingdom, and North America.

For further information, please contact:

Investor Relations
Telephone: 1 (604) 343-2977
E-mail: investors@love-pharma.com
www.love-pharma.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management's current beliefs and is based on

information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "predicts", "intends", "targets", "aims", "anticipates", "may" or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions, risks relating to epidemics or pandemics such as COVID-19, including the impact of COVID-19 on the Company's business, financial condition and results of operations, lack of investor demand for Bitcoin and/or Bitcoin futures exchange traded funds, and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.